



## **Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference**

May 13, 2020

MONROVIA, Calif.--(BUSINESS WIRE)--May 13, 2020-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020 at 4:15 p.m. ET / 1:15 p.m. PT.

A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at [www.xencor.com](http://www.xencor.com). A replay will be posted on the Xencor website approximately one hour after the live event and will be available for 30 days.

### **About Xencor, Inc.**

Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 17 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit [www.xencor.com](http://www.xencor.com).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20200513005208/en/): <https://www.businesswire.com/news/home/20200513005208/en/>

Charles Liles  
626-737-8118  
[cliles@xencor.com](mailto:cliles@xencor.com)

Media Contact  
Jason I. Spark  
Canale Communications  
619-849-6005  
[jason@canalecomm.com](mailto:jason@canalecomm.com)

Source: Xencor, Inc.